ITGAM and central nervous system cancer: Notably, CD11b-expressing glioma-associated microglia/macrophages (GAMMs) have been successfully targeted in preclinical models, using a bifunctional anti-CD11b antibody conjugated with 89Zr (PET imaging) and 177Lu (therapy), leading to reduced TAMCs and enhanced immunotherapy outcomes [11].